REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing ServicesBELTSVILLE, Md.,…
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a…
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
February 22, 2026 16:00 ET | Source: Dyne Therapeutics, Inc. - Late-breaking…
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical…
ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx),…
FDA 510(k) Clearance Establishes Broad Intended Use for Copan’s PhenoMATRIX, Expanding Clinical Microbiology Capabilities
MURRIETA, Calif., Feb. 17, 2026 /PRNewswire/ -- Copan Group announced today that…
Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled…
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE:…
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
